From repairing tissues to transporting oxygen in the body, proteins have many important functions. Studying the proteome, the complete proteome expressed by organisms, can reveal new information about organisms and can help prevent or treat disease. Life sciences company
Seer is commercializing a new platform for proteomics, proteomics research. Using proprietary engineered nanoparticles, automated instruments, consumables, and software packages, the company can perform large-scale deep proteomic analysis in just a few hours.
Nano Solutions for Big Problems
Todays Seer platform was not originally inspired by proteomics. Seer CEO Omid Farokhzad explained that they have developed different nanotechnologies for medical applications. Many nanotechnologies are used for drug management and some are used for vaccines. But when they are exposed to biological systems, one of the problems they encounter is nanoparticles.
Farokhzad described how the team injected nanoparticles into the body to deliver drugs. But when nanoparticles hit human plasma or blood, they will form a layer of biomolecules and proteins on its surface.
Seer’s Proteograph ™ suite of products for rapid and unbiased large-scale proteomic experiments. SEER
more for you
warehouse robot company Berkshire Gray stock debut on Nasdaq: “There’s a big gap”
Pivot Bio is valued at close to $ 2 billion as it raised up to $ 430 million for replace synthetic fertilizer in corn and wheat 444 Stuckey’s comeback plan: starting with candy making and ending with store
“At first, we didn’t like it because we thought it would destroy the original nanoparticles we designed for therapeutic applications”, Farokhzad said. “It turns out that we were very wrong. The binding of these macromolecules and proteins to the surface of the nanoparticles is very precise and important. This combination occurs due to the physical and chemical properties of the nanoparticles.
Millions of years of biological evolution have created proteins designed to bind together. This is how they work, they come together to form the unit that is the basis of life. Proteins stick together because the physical and chemical properties of one protein match the properties of another protein. In the human body, proteins can only be combined when they are expressed at the same place and time.
“At Seer, we solve the problem of location and time by placing proteins in the same 96-well plate in the laboratory. We control physical and chemical properties through engineering, machine learning, and data science. Farokhzad said that by understanding the proteome, we can learn more about the complexity of proteins and how they work together.
reveals complexity
In the past, proteomics methods were biased or targeted, and relied on the use of ligands (molecular binding) to find proteins. The average length of a human protein is 470 amino acids, but the average ligand binds only 5 to 8 amino acids. The targeted approach means that the huge complexity of the proteome is lost.
Protein-coated nanoparticles.
A protein-coated nanoparticle. SEER
Seer’s technology can examine the entire proteome by combining different nanoparticles in proportions and speeds in one panel. It is not a targeted method, but an unbiased method by examining every amino acid in the protein.
“We are born with about 20,000 genes, and all of our cells have the same genes. But biology is complicated. When you move from the genome to the proteome, you end up with 1 million to 4 million proteins,” Farokhzad said.
Humans produce new proteins every day. When we interact with the environment, our proteome will respond accordingly. Change occurs. Proteomics is
. What the future looks like
When proteomics and genomics are combined, they created the field of protein genomics, and Farokhzad believes there is great potential here. “When we understand the complexity of the genome at the functional level, our lives will change. New possibilities and markets will open,” Farokhzad said.
For example, many neurodegenerative changes occur at protein levels in the human body, so studying genes is not enough to fully understand them. Protegenomics opens up the possibility of learning more about Alzheimer’s disease, dementia, and multiple sclerosis (MS). In addition, because everyone has a different proteome, being able to study individual proteome will bring better personalized medicine and cost savings through early disease detection.
“When a large amount of biological data becomes available, a whole new world will be created. Think about our incredible access to content on the Internet now. We can catalog it, use it, and take advantage of it,” says Rohzad.
Understanding the proteome can open up many possibilities for healthcare and other industries. Protein genomics can take this knowledge to a new level by combining this knowledge with the genome and using data.
Thanks to Lana Bandoim for research and additional reporting on this article. I am the founder of SynBioBeta, and some of the companies I write are sponsors of SynBioBeta conferences and weekly reviews.

By Peter

Leave a Reply

Your email address will not be published. Required fields are marked *